Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Novartis (SIX:NOVN) reported a 24% surge in Q2 net income to $4 billion, driven by robust demand for key therapies like Kisqali, Entresto, and Kesimpta. Earnings per share rose 29% to $2.07, supported by a lower average share count. Revenue climbed 12% to $14.1 billion, with U.S. sales up 21% to $6.2 billion and international sales growing 6% to $7.8 billion.
The company saw strong volume growth of 12%, partially offset by a 2-point decline from generic competition. Pricing and currency each contributed a 1-point gain. Kisqali revenue soared 64% to $1.2 billion, Entresto jumped 24% to $2.4 billion, and Kesimpta rose 35% to $1.1 billion. Scemblix and Leqvio each posted $298 million in sales, up 82% and 64% respectively. Cosentyx grew 7% to $1.6 billion.
Operating income increased 21% to $4.9 billion, boosting the margin to 34.6% from 32.1%. Core operating income rose 20% to $5.9 billion, with the core margin improving to 42.2% from 39.6%. Gross profit rose to $11.5 billion, while cost of goods sold fell to 23.6% of sales.
R&D spending rose 15% to $2.7 billion. SG&A costs increased to $3.4 billion but declined slightly as a percentage of sales. Free cash flow surged 37% to $6.3 billion.
For H1 2025, Novartis posted a 29% increase in net income to $7.6 billion on $27.3 billion in sales. Free cash flow rose 46% to $9.7 billion. Oncology sales rose 22% to $4.3 billion, cardiovascular therapies surged 28% to $2.7 billion, and neuroscience grew 19% to $1.5 billion. Net debt increased to $23.8 billion following $13.3 billion in dividend and buyback outflows.
